HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics-subgroup analysis Meeting Abstract


Authors: Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; Touzeau, C.; Amor, A. A.; Paner, A.; Maisel, C.; Mazumder, A.; Raptis, A.; Puig, N.; Harmenberg, J.; Gustavsson, B.; Thuresson, M.; Richardson, P. G.
Abstract Title: HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics-subgroup analysis
Meeting Title: 62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 136
Issue: Suppl. 1
Meeting Dates: 2020 Dec 5-8
Meeting Location: Virtual
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2020-11-05
Language: English
ACCESSION: WOS:000607547203016
DOI: 10.1182/blood-2020-136002
PROVIDER: wos
Notes: Meeting Abstract: 41 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hani Hassoun
    329 Hassoun